Filtered By:
Source: PharmacoEconomics
Drug: Activase
Management: National Institute for Health and Clinical Excelle
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective
Abstract
The National Institute for Health and Care Excellence (NICE) invited Boehringer Ingelheim GmbH, the manufacturer of alteplase, to submit evidence for the clinical and cost-effectiveness of alteplase for the prevention of strokes within a 0–4.5 h window. The comparator was standard medical and supportive management that does not include alteplase. This paper provides a description of the company submission, the Evidence Review Group (ERG) review and NICE's subsequent decisions. Clinical effectiveness evidence for alteplase was derived from 5 trials. For the 3–4.5 h treatment window, alteplase did not...
Source: PharmacoEconomics - November 26, 2014 Category: Health Management Source Type: research
